Asset profile
Camizestrant
Small molecule
Evidence outlook
Approved: hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative,... (FDA)
This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational. Regulatory approval supersedes design-level evidence grading for the approved use.
track record: Weak signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
67 competitors in this universe: 7 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 29 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Camizestrant: this drug | Phase 3 | Small molecule | Estrogen receptor | ||
| Elacestrant | Approved | Small molecule | Estrogen receptor | ||
| Fulvestrant (Faslodex) | Approved | Small molecule | Estrogen receptor | ||
| Imlunestrant | Approved | Small molecule | Estrogen receptor | ||
| Tamoxifen | Approved | Small molecule | Estrogen receptor | ||
| Vepdegestrant | Approved | Small molecule | Estrogen receptor | ||
| Giredestrant | Phase 3 | Small molecule | Estrogen receptor | ||
| Palazestrant | Phase 3 | Small molecule | Estrogen receptor | ||
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | ||
| Alpelisib (BYL719) | Approved | Small molecule | PI3K-alpha | ||
| Anastrozole | Approved | Small molecule | Aromatase | ||
| Capecitabine | Approved | Small molecule | Fluoropyrimidine (antimetabolite) | ||
| Capivasertib | Approved | Small molecule | AKT (inhibitor) | ||
| Datopotamab Deruxtecan | Approved | Antibody–drug conjugate | TROP2 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Docetaxel | Approved | Small molecule | Microtubules (tubulin) |
…and 52 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
1 further head-to-head pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(8 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (4)
April 2027 (1)
What to watch
May 2027 (1)
What to watch
August 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (1)
February 2028 (1)
What to watch
2029 (2)
2030 (1)
March 2030 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.